{"name":"Prevail Therapeutics","slug":"prevail-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":48798000,"netIncome":-63188000,"cash":168051000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Optional Prednisone","genericName":"Optional Prednisone","slug":"optional-prednisone","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Optional Prednisone","genericName":"Optional Prednisone","slug":"optional-prednisone","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPV21tSnZtMmpoQUZwbzZDaGstMnRYdzUyNmxseXNtUXpGTFRoZi1KR2FJbVNWOXdTRVZhUzZESVVWVmRNbk9rMW05dEUxXy1ScXBLRXpCMW12TDZoOHBhTVJ2aTRnbmVfeFh0bHdvZ0Q0WjBiNVNjUThpNzJTMUR6eVd0M2EzcFQwS1R0MGZ2Vk93YUNhdzA3eEhMcVdnMXdnZnZvckxR?oc=5","date":"2026-02-05","type":"trial","source":"Clinical Trials Arena","summary":"Lilly stops development of three drugs, including gene therapy - Clinical Trials Arena","headline":"Lilly stops development of three drugs, including gene therapy","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNaFctTzM2TXNIc0hTU1NLN2xQR2xweXd6ZUUxWnlnSUxfdUNDSTNrNGtvekNIQ0xlLUJSaVhISGxuTkU2aUtqQlRCMzJvb3M1UUJjWU9YSjM2MzNMZ0pGd3pzNGR1VE52LUI5V1o4YWZBMTk1Zm5XRHRubTlLZE53RG1Ca0xSVlFLVC1hSGE4eG1YU1Q3Qzd3bA?oc=5","date":"2026-02-05","type":"pipeline","source":"BioSpace","summary":"Lilly Axes 3 Therapies Amid Pipeline-in-a-Product Push for GLP-1 - BioSpace","headline":"Lilly Axes 3 Therapies Amid Pipeline-in-a-Product Push for GLP-1","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQWDQzY0lDS3dsd0pfejJsdzJPMDZhOFAxV2x3cmd6TjNSd2dJWjBmenZyczU0aFBaOVJHd2JkcEFVUkZaQUtudTFrVU12LUxCV0dLa2NlY0JFVExXTHJtS0VXcEUwUGtvX1JnNVI2TEZXcEJKb0kwRDdIdU1naElMTmJUOExPWDFiN2RobWtlTzcxeHZJcHEyS2cwSDJpVDZTTzI0UWN4UzM4LWlYZExzeXpUMmhjdw?oc=5","date":"2026-02-05","type":"pipeline","source":"StockStory","summary":"Why Eli Lilly (LLY) Shares Are Getting Obliterated Today - StockStory","headline":"Why Eli Lilly (LLY) Shares Are Getting Obliterated Today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOdUNreXBUMGt0Q05KYVJ3T09oeHZjQ1hWS2ZUU2g0S05yOTFCMjNmLTMwTGpJSDJOYkduWkFIZ1Q2ZjFUVFZnT2paeUtQUXNYa1N1TGdSYlZzYVAtV1VpeVFtRkVlZmZQd0JlX0NPcUxGODJMS0hXV2NUY2JrTTl1eXNyb2ZnOENGaUx0VUJfdVNOc3dhRzFPdnpvRl9DOUhkRF9uQmplRzVaOW8?oc=5","date":"2026-02-04","type":"deal","source":"Fierce Biotech","summary":"Lilly drops 3 pipeline drugs, including gene therapy from $1B Prevail buyout - Fierce Biotech","headline":"Lilly drops 3 pipeline drugs, including gene therapy from $1B Prevail buyout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNTFh0QWdFTGtiQlJhazA3ZmxORk9DOW5pUTJrcGNBRmxyNXRJWllQU3FTczdFaVFVVjJ2dEpPZWZjUTdUVXdUcU9waEdzUGp4THNkaG1ya0MyUllQNjdIb3g5SWcyY3JtYVRPRzByb21fcmd4NVZ1TzFFV3NGa2pkLUJNTVhJbWVyRzZjbzNMWmtGc0djc05EVVpfbWpQMUx6dUdpTjFrNE9WaThaaXJiZnBEZ2tLT3dGNmp3?oc=5","date":"2025-11-10","type":"deal","source":"MedCity News","summary":"Eli Lilly Strikes Another Genetic Meds Deal, Gaining Global Rights to MeiraGTx Retinal Gene Therapy - MedCity News","headline":"Eli Lilly Strikes Another Genetic Meds Deal, Gaining Global Rights to MeiraGTx Retinal Gene Therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOTHBSTnlxejBvb3FiUmVHVTRMSjhSdFhjZl9ZcGx3aHlYdC1yQTNEMXQ5WThNTk9MTE9WOURSX1Y3ZXNyQ0ctc1I1ckFGYlV2djNFWXZ6Y2p3cGdYZVRqekZ2SlpyaU84WVFQUHlvZlA0MlVfQUVReWY4SUVJcDBFOEdVSDE1eUVDUEplTEVER1hZeEpOd1dYM01GT0xpeGd0?oc=5","date":"2025-05-06","type":"regulatory","source":"Pharmaceutical Technology","summary":"Eli Lilly signs $415m deal for Alchemab’s ALS therapy - Pharmaceutical Technology","headline":"Eli Lilly signs $415m deal for Alchemab’s ALS therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxPVk9kVlJSMzlodE44ZHlOeFBWdjE5YUZob0hPVGRFZ2VoMGdTV0x1bWRsZVZ4a1B3ZHIxVGd1UlJfbFVBM3E2SFl4UzRGc3NIb0tmeVEyd05zRG5UcURvdW95ZENMTmoxWURlV0I3Wkpwc2ZyOWZxMDVic2VmSHp4VTZlVEZmVjhOLU9CRlpyblFkMmpyeUJ3YTk0cE4waGZkbnZwN3pzdDhLbXhRbXl0TUdIbDh0UzJBZ0xLVV93YlFIMnVyakZpRUIyY0sxTEVycWVweHJvVDhkOXZodHFBazZENWdpclZjMHJGRmpB?oc=5","date":"2025-04-28","type":"deal","source":"CRISPR Medicine News","summary":"Press Release Service: Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division, and Announces ASGCT Joint Presentation on Self","headline":"Press Release Service: Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxPZ19DaTFfd0d5a1N6djhRNEhSYVRZbjZQUHh5RkxPWjgtbldkM3AzM2pMVW16a2R5c2M3Z0VGQm9UWVJES1d5VjJpV0hMZ3VydEZSTWZUMEozUFdrVHlXYjgzVnc5TEphTDY2WWVGWEY4dTVERG1WNWlYcWdmbWJVQlJES2JqalRrbmhFSi1IYWlUVVZKcHp5YWd2TV9LU3Y2Z1VaYXpPMy11U01ZbUJscFRYTWJnazcwcjlGb1lyT3hja1BCem1OamFBR1Nxc09mMXJGREtwdkZ1a3U3VTBjMFdqdE5MeWhfNk51XzFvVFd2dGtubFFFVEwxOVMyWk9sejFsMFBKdFk3aENxZjFjM1Y1YXliaW84cThvNDJ0NGtiZDVBSWJuQ2JSbHRzTHJWTVBLVGdPd2I1TmxHQnc?oc=5","date":"2023-01-04","type":"deal","source":"PR Newswire","summary":"Capsida Biotherapeutics Announces Strategic Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Develop Non-Invasive Gene Therapies for CNS Diseases - PR Newswire","headline":"Capsida Biotherapeutics Announces Strategic Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Develop N","sentiment":"neutral"},{"date":"2021-01-29","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC","headline":"SC 13G Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPX19QU29LbGJ3Z2hnSERLNVhNWjRxRXpnSlZHRHpPV1J5MnU5bTlFNVRPNGNheFB6VzBsVTFqd0J2dDlVcTdMMHlqOEFxOFNla0dUSXFSMGhyR1lMalcxOVo5TVJxMGt0Wk5TZUNiMHcyTzN2alBLaTAtNzRyNk5uaUNnTVNaME4xSm00OWwzM2FxRjUtc3RRZGhseDlISWM?oc=5","date":"2021-01-25","type":"pipeline","source":"PharmTech.com","summary":"Eli Lilly Completes $1.5 Billion Acquisition of Prevail Therapeutics - PharmTech.com","headline":"Eli Lilly Completes $1.5 Billion Acquisition of Prevail Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQdUplOVNCY3l4bjQ4WDJrQWVhc0Z0dm4zTnBTRUxuQk1lUnJqLXVVZzVpSXgyOHpHSE9wMlhhWnNJZ2JvTlloOXRuMlpRdHF3bTA2M2hEWldRME0wMDRoVkQxMER4aUx0UWVCUGEtQUJ6Vy1KY2JycmpGZFcxNTRsb2loRnJ5b2I2SHMzSndNSzJ5SmFCYWdySDhtRHU3UXk3MnIzSVlqczNyNkVQUUVlYkFNc0VKOUE?oc=5","date":"2020-12-15","type":"deal","source":"Eli Lilly","summary":"Lilly Announces Agreement to Acquire Prevail Therapeutics - Eli Lilly","headline":"Lilly Announces Agreement to Acquire Prevail Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNaUw4NnMzcEMtTGJYeXEwTWxZV0xmaFpYbEdteGp2UjhMOHpWeDl5VlN4SEpxSWFVUUNaNVhVTXdrV1NIQU12T2tOTzN6ZkZMZFZ2d0c5TExCdHhlUUhjWlJnNXI3WnkxNGxJYWsxeTh3RmpPMjBQaklSX1V4M1BmaHJvTnpvQ19XWHRTcDRLeWMzTldCRVMtcS1B?oc=5","date":"2020-12-15","type":"deal","source":"Contract Pharma","summary":"Lilly to Acquire Prevail Therapeutics in $1B Deal - Contract Pharma","headline":"Lilly to Acquire Prevail Therapeutics in $1B Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPQ05XdXVVdVZadVI0Tl8yZi13WURDTGt1Xy1XQi1DSHpYcWxxZUdwWExYbmZ6T0VRWlhORGNocm56Q2xyMlpnT3hoVkd1T3ZqSThLVEVKNG00UXR0XzdQNndRSlVkaERNNlYzRDdadEw2ZlNFWTNiakc0bUUwa29oQUIxNWxuZDBibGJ4SGNRYzVVUUJvX0ZNaGFSdFl1SjZJVm9UcnM1bG0zZU9y?oc=5","date":"2020-12-15","type":"pipeline","source":"BioPharma Dive","summary":"Lilly pays $880M for Prevail, pushing further into genetic medicine - BioPharma Dive","headline":"Lilly pays $880M for Prevail, pushing further into genetic medicine","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":48798000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-63188000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":168051000,"cashHistory":[],"totalAssets":187102000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}